A new, U.S. Food and Drug Administration-approved nonsurgical treatment for fecal incontinence was made available Thursday to select centers of excellence in the United States. The University of Alabama at Birmingham is among the first to offer the innovative system.
Expert urogynecologist Holly E. Richter, PhD, MD, director of the UAB Division of Urogynecology and Pelvic Reconstructive Surgery, was the principal investigator of a study that provided data to the FDA for clearance of the Eclipse System. As part of her study, Dr. Richter conducted a trial of the system with a local patient who suffered from fecal incontinence. Thus far, the Eclipse System has proven successful.
"The Eclipse System is a nonsurgical therapy that can be used early in the treatment pathway," said Dr. Richter. "The Eclipse is an easily tried approach that fills a gap between lifestyle changes in diet and exercise and more invasive treatments. I'm excited that this new option will soon be available to patients here in Alabama."
To learn more about the UAB trial or watch a video of the patient's experience, click here.
More articles on medical innovations:
Feeling unprepared for precision medicine? You're in good company
Light-activated nanoparticles able to target, dispatch antibiotic-resistant superbugs
Biotechnology company develops potential biofilm-busting treatment for infections